CTC and Immune Cell Profiles in Triple-Negative Breast Cancer Patients

Twenty-three female patients newly diagnosed with triple-negative breast cancer (TNBC) were recruited from a private clinic in Johannesburg, Gauteng. The dataset, created by Yshrene Naidoo and last updated in May 2026, contains flow cytometry and ELISA assay results quantifying circulating tumor cells, immune cell subsets, and soluble biomarkers in patient blood samples compared to healthy controls.

Use Cases

• Classify immune cell population differences based on flow cytometry counts of CD4+ and CD8+ T-cells, B-cells, and NK cells.
• Analyze biomarker concentration patterns based on ELISA measurements of IL-1RA, IFN-γ, HMGB1, and other soluble factors.
• Investigate correlations between circulating endothelial cell markers (CD146, VEGFR2) and metastatic cancer types mentioned in the description.

Strengths

• Includes data from 23 treatment-naïve TNBC patients with detailed demographic and consent records.
• Assays measure a wide panel of targets, including EpCAM, cytokeratin, 10+ immune markers, and 10+ soluble biomarkers.
• Data is openly shared under a CC-BY-4.0 license, facilitating reuse.

Limitations

• Row count is unknown, which may limit suitability assessment for large-scale ML.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data reflects a specific cohort from a single clinic in Johannesburg, which may limit generalizability.

Provenance

Source

figshare, author Yshrene Naidoo.

Collection Method

Flow cytometry and enzyme-linked immunosorbent assays (ELISA) performed on peripheral blood samples.

Time Range

Study period not specified; dataset last updated May 2026.

Freshness

Last updated 2026-05-06 08:25:01; freshness should be verified.

Geography

Patients recruited from a private clinic in Johannesburg, Gauteng, South Africa.